Polarean Imaging Plc

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BF3DT583
GBP
0.00
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Risky -

  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -91.72%, its profits have fallen by -9.3%
2

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 2 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.91

stock-summary
Return on Equity

-128.79%

stock-summary
Price to Book

0.27

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-87.37%
0%
-87.37%
6 Months
-91.3%
0%
-91.3%
1 Year
-91.72%
0%
-91.72%
2 Years
-97.13%
0%
-97.13%
3 Years
-99.74%
0%
-99.74%
4 Years
-99.74%
0%
-99.74%
5 Years
-99.82%
0%
-99.82%

Polarean Imaging Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
2.27%
EBIT Growth (5y)
-16.99%
EBIT to Interest (avg)
-8.73
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.11
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.11
EV to EBIT
-0.15
EV to EBITDA
-0.17
EV to Capital Employed
1.19
EV to Sales
0.60
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-774.23%
ROE (Latest)
-128.79%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Polarean Imaging Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is -11.11% vs 50.00% in Dec 2021",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -10.78% vs -100.00% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.80",
          "val2": "0.90",
          "chgp": "-11.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.30",
          "val2": "-9.70",
          "chgp": "-6.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.30",
          "val2": "-10.20",
          "chgp": "-10.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-13,233.80%",
          "val2": "-12,077.00%",
          "chgp": "-115.68%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
0.80
0.90
-11.11%
Operating Profit (PBDIT) excl Other Income
-10.30
-9.70
-6.19%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-11.30
-10.20
-10.78%
Operating Profit Margin (Excl OI)
-13,233.80%
-12,077.00%
-115.68%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is -11.11% vs 50.00% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -10.78% vs -100.00% in Dec 2021

stock-summaryCompany CV
About Polarean Imaging Plc stock-summary
stock-summary
Polarean Imaging Plc
Pharmaceuticals & Biotechnology
Polarean Imaging Plc is a medical drug-devising company. The Company with its subsidiaries operates in the medical imaging market and develops equipment to enable existing magnetic resonance imaging (MRI) systems. The Company focuses on improving the level of pulmonary functional imaging, and specializing the use of polarised Xenon gas (129Xe) as an imaging agent to visualize ventilation, and gas exchange. The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required for imaging 129Xe in the MRI system. The United States food and drug administration (FDA) has accepted the group’s III clinical trial and design.
Company Coordinates stock-summary
Company Details
2500 Meridian Pkwy Ste 175 , DURHAM NC : 27713-4214
stock-summary
Tel: 1 919 2067900
stock-summary
Registrar Details